413 related articles for article (PubMed ID: 34477066)
1. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.
Liu RC; Consuegra G; Chou S; Fernandez Peñas P
Clin Exp Dermatol; 2019 Aug; 44(6):643-646. PubMed ID: 30618056
[TBL] [Abstract][Full Text] [Related]
3. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma.
Lolli C; Medri M; Ricci M; Schepisi G; Filograna A; De Giorgi U; Stanganelli I
Medicine (Baltimore); 2018 Dec; 97(52):e13810. PubMed ID: 30593172
[TBL] [Abstract][Full Text] [Related]
4. Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review.
Zekić T; Benić MS
Rheumatol Int; 2023 Mar; 43(3):559-565. PubMed ID: 36449057
[TBL] [Abstract][Full Text] [Related]
5. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
George G; Schmidt L; Tolat P; Riese M; Kilari D
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
[TBL] [Abstract][Full Text] [Related]
6. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
7. Widespread vitiligo and poliosis following ipilimumab-nivolumab combination therapy.
Nemovi K; Jamali A; Matinpour K; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1278-1282. PubMed ID: 36785936
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study.
Guida M; Strippoli S; Maule M; Quaglino P; Ramondetta A; Chiaron Sileni V; Antonini Cappellini G; Queirolo P; Ridolfi L; Del Vecchio M; Cocorocchio E; Di Giacomo AM; Festino L; Merelli B; Occelli M; Brugnara S; Minisini A; Sava S; Tommasi S; De Summa S;
ESMO Open; 2021 Apr; 6(2):100064. PubMed ID: 33711672
[TBL] [Abstract][Full Text] [Related]
9. Clinical Presentation and Prognostic Features in Patients with Immunotherapy-Induced Vitiligo-like Depigmentation: A Monocentric Prospective Observational Study.
Hermann N; Maul LV; Ameri M; Traidl S; Ziadlou R; Papageorgiou K; Kolm I; Levesque M; Maul JT; Brüggen MC
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230498
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.
Rao H; Guo Z; Wen X; Zeng X; Wu L; Huang L
Front Oncol; 2022; 12():1099108. PubMed ID: 36713515
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
Edmondson LA; Smith LV; Mallik A
J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
[TBL] [Abstract][Full Text] [Related]
12. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
Weiss SA; Djureinovic D; Jessel S; Krykbaeva I; Zhang L; Jilaveanu L; Ralabate A; Johnson B; Levit NS; Anderson G; Zelterman D; Wei W; Mahajan A; Trifan O; Bosenberg M; Kaech SM; Perry CJ; Damsky W; Gettinger S; Sznol M; Hurwitz M; Kluger HM
Clin Cancer Res; 2021 Sep; 27(17):4757-4767. PubMed ID: 34140403
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report.
Ngo L; Miller E; Valen P; Gertner E
J Med Case Rep; 2018 Feb; 12(1):48. PubMed ID: 29478412
[TBL] [Abstract][Full Text] [Related]
16. Folliculotropic Cutaneous Metastases and Lymphangitis Carcinomatosa: When Cutaneous Metastases of Breast Carcinoma Are Mistaken for Cutaneous Infections.
Paolino G; Panetta C; Didona D; Donati M; Donati P
Acta Dermatovenerol Croat; 2016 Jun; 24(2):154-7. PubMed ID: 27477179
[TBL] [Abstract][Full Text] [Related]
17. Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.
Carbone ML; Capone A; Guercio M; Reddel S; Silvestris DA; Lulli D; Ramondino C; Peluso D; Quintarelli C; Volpe E; Failla CM
Front Immunol; 2023; 14():1197630. PubMed ID: 37680638
[TBL] [Abstract][Full Text] [Related]
18. Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report.
Shibata Y; Noguchi G; Suzuki T; Osaka K; Umemoto S; Kishida T
Am J Case Rep; 2021 Aug; 22():e932924. PubMed ID: 34358221
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y
Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Brahmer JR; Drake CG; Wollner I; Powderly JD; Picus J; Sharfman WH; Stankevich E; Pons A; Salay TM; McMiller TL; Gilson MM; Wang C; Selby M; Taube JM; Anders R; Chen L; Korman AJ; Pardoll DM; Lowy I; Topalian SL
J Clin Oncol; 2010 Jul; 28(19):3167-75. PubMed ID: 20516446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
